MW:57,000
ExtinctionCoefficient:1.97

Lyophilizedfrom11.9mMphosphate,137mMNaCl,2.7mMKCl,pH7.4.

Storage:-20°C

BuyPurifiedNativeHumanHemopexin,HumanPlasma,LowEndotoxinLevel
Price$340.00/mg.BulkQtyAvailable.

Hemopexinisasingle-chainproteinbelongingtothefamilyofbloodtransportproteins.Itbindstohemereleasedintothebloodstreamduringthedegradationprocess.Recentstudieshavedemonstratedthathemopexinactsasanextracellularantioxidantagainsthemoglobin-mediateddamageininflammation.Hemopexinprotectsagainsthemetoxicityandconservesandrecyclesiron.Abnormallevelsofhemopexinareassociatedwithhemolyticanemia,chronicneuromusculardisease,andacuteintermittentporphyria.

Purity:>=95%bySDS-PAGE.
EU:<1.0 EU/mg by fluorogenic assay, Lonza,50-658U

Ref:Strop,P.,etal.1981.J.Chromat.214,317;Miller,Y.I.,etal.1996.Biochem.35,13112.

PreparedfromplasmashowntobenonreactiveforHBsAg,anti-HCV,anti-HBc,andnegativeforanti-HIV1&2byFDAapprovedtests.

AthensResearch&TechnologyproductsarelaboratoryreagentsandarenottobeadmiNISTeredtohumansorusedforanydrugpurpose.Forresearchuseonly.

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.